🇺🇸

US SEC Filing Intelligence

· daily

US Corporate Distress Financial Stress SEC Filings — March 19, 2026

Across 50 filings in the USA Corporate Distress & Bankruptcy stream (34 new), dominant themes include aggressive liquidity raises via high-interest debt ($225M American Vanguard term loan, $3.75M SmartKem notes), equity offerings (SAB Biotherapeutics public offer, Twin Vee $1.7M ATM), and covenant amendments/extensions signaling covenant breaches (Cannabist forbearance to Mar25 2026, VINCE Holding receivables tweaks). Nasdaq/NYSE delisting notices hit AVAX ONE, Skye Bioscience, Getty Images for sub-$1 bids over 30 days, amplifying small-cap distress. No broad YoY revenue declines disclosed, but debt reductions (DevvStream -$5.9M net) and refinancings (Wolfspeed $475.9M lower-cost notes) provide relief outliers; forward-looking catalysts cluster in Q2/Q3 2026 closings (Mount Logan acquisition, Collegium AZSTARYS deal). Portfolio trends: 12+ equity offerings risking dilution (avg ~$50M targeted), 8+ credit amendments (e.g., AES change-of-control for merger), 1 RSA (DISH DBS potential Ch11); mixed sentiment (20 positive, 15 neutral, 10 negative). Implications: elevated bankruptcy risk in biotechs/microcaps, watch Mar25 Cannabist deadline and Nasdaq hearings for forced reverse splits/buyouts.

50 high priority 50 total filings
· daily

US SEC Trading Suspension Halt Orders — March 19, 2026

Three US-listed companies—AVAX One Technology Ltd. (Nasdaq), Skye Bioscience, Inc. (Nasdaq), and Getty Images Holdings, Inc. (NYSE)—received deficiency notices between March 13-17, 2026, for common stock bid/closing prices below $1.00 for 30 consecutive business/trading days, violating Nasdaq Listing Rules 5550(a)(2)/5450(a)(1) and NYSE Section 802.01C. This represents a uniform 30-day period-over-period price decline trend across all filings, signaling broad weakness in share prices with no YoY/QoQ recovery mentioned. No immediate trading suspensions occurred, but high materiality (9/10) and negative sentiment underscore delisting risks, with AVAX securing a hearing stay, Skye gaining 180 calendar days to September 14, 2026, and Getty a six-month cure period. Forward-looking paths include potential reverse stock splits (explicit for Skye, implied elsewhere) and compliance via 10 consecutive days at or above $1.00, though no assurances provided. Portfolio-level pattern: cross-sector small-cap distress (tech, biotech, media), amplifying volatility and potential OTC transfers. Implications include heightened short interest, dilution risks from splits, and time-sensitive catalysts for investor positioning.

3 high priority 3 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 19, 2026

Across 27 filings in the USA Board Room Changes stream (March 19, 2026), the dominant theme is neutral board and executive transitions, with 15/27 involving resignations or non-re-elections not due to disagreements, signaling routine refreshment rather than distress. Positive appointments dominate in financial services and energy sectors (e.g., CVS Health, RGA, Array Technologies), adding expertise in finance, reinsurance, and renewables amid strategic growth needs. Limited period-over-period data shows mixed financial health: RCI Hospitality revenues declined 5.5% YoY to $279.4M with Adjusted EBITDA down to $52.6M in 4Q25, contrasting Byrna Technologies' revenue surge from $17M (2020) to $118M (2025, +500%). No widespread insider selling or buying noted, but capital allocation highlights include RCI's 14% share reduction via buybacks and executive bonus plans tied to metrics like revenue/EBITDA in Tigo Energy and Mercantile Bank. Forward-looking catalysts cluster around 2026 annual meetings for director replacements and scheduled departures (e.g., Clear Secure GC April 3). Overall, low materiality (avg 5.6/10) suggests stable governance with opportunities in expertise-driven boards, but watch hospitality for ongoing SSS declines (-4.4% 4Q25).

27 high priority 27 total filings
· daily

US Merger & Acquisition SEC Filings — March 19, 2026

The USA M&A & Takeover Activity stream reveals intense SPAC activity across 10/12 filings, with new IPOs (Metals Acquisition Corp II $230M, Praetorian $253M total), over-allotment exercises, and multiple BCA extensions (Pyrophyte 5th amendment to Apr 2027, Blue incentive pool to 8%), signaling prolonged deal hunts amid market appetite for fresh capital. Ashford Hospitality Trust's $56.8M hotel sale drove pro forma revenue decline of 1.5% YoY to $1.15B (YE2024) but improved net loss 17% to $68.5M, reflecting deleveraging. Battalion Oil's all-stock acquisition added 7,090 acres and 30 drilling locations, expanding contiguous holdings 35% to 27,097 acres. No insider trading reported; capital allocation focuses on trust funding (Constellation note to $5.25M) and debt repayment. Period trends show stable/no declines in most SPACs, mixed in hospitality; forward deadlines cluster Q2 2026-Q1 2027, building catalyst calendar. Portfolio-level: 7/12 neutral sentiment, 3 positive IPO/amendments, implying SPAC resilience but extension fatigue risk.

12 high priority 12 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 19, 2026

Across 50 overnight SEC filings, standout revenue accelerations dominate in semiconductors (Micron +196% YoY to $23.9B) and biotech (argenx +90% YoY sales to $4.15B), contrasting with declines in digital health (DarioHealth -17% YoY to $22.4M) and energy (Equinor -2.5% YoY to $43.8B), highlighting sector divergence amid mixed economic signals. Airlines (Republic +13.7% YoY revenue) and solar (SUNation +26% FY to $71.9M, beating guidance) show resilience, while SPACs (Artius II, Rice Acquisition) report trust interest offsetting losses but extended deal timelines signal delays. Capital allocation leans positive with steady dividends (Modiv $0.10/month common, Global Net Lease preferreds) and repurchases (News Corp $1B program), but debt stresses emerge (Cannabist forbearance extension, American Vanguard $225M term loan at SOFR+8.25%). Merger catalysts near (RYVYL 99% votes cast, reconvene 3/25) and routine ABS servicing compliance in 20+ filings indicate stable structured finance. Portfolio trend: 7/15 high-materiality filings show revenue growth >20% YoY averaging +80%, but 4 report cash burn or dilution; implications favor selective longs in semis/biotech pre-open.

37 high priority 13 medium 50 total filings
· daily

Biotech Small-Cap Approvals — March 18, 2026

FDA approved four original ANDA generics for small-cap biotech sponsors on March 12-13, 2026, spanning PHYTONADIONE, Citalopram Hydrobromide, Potassium Phosphate Dibasic, and Dextromethorphan Hydrobromide—all under standard review with no special designations or specified indications. This cluster signals routine pipeline progress enabling near-term generic entries but highlights zero innovative upside amid pervasive pricing and competitive pressures. Neutral overall for portfolios; monitor launches for modest revenue contributions without differentiation.

4 total filings
· daily

New Drug Approvals (Original) — March 18, 2026

FDA approved four original ANDAs on March 12-13, 2026, for generics from ORBICULAR (phytonadione), Aurobindo Pharma Ltd (citalopram hydrobromide), CAPLIN (potassium phosphate dibasic), and Hetero Labs Ltd III (dextromethorphan hydrobromide), all under standard review with no special designations and unspecified indications/therapeutic areas. These routine approvals signal neutral portfolio additions for sponsors amid typical generic dynamics. No material bullish/bearish divergences; focus on execution risks in commoditized markets.

4 total filings
· daily

Contract Option Exercises — March 18, 2026

NASA's $109.2M delivery order to Caltech (JPL FFRDC) for EMIT Earth mineral dust investigation and operations through 2028 underscores stable long-term federal space R&D funding, with $90.3M outlayed to date. Neutral direct equity implications due to nonprofit recipient, but $16.2M unexercised options signal potential modest upside. Single-record concentration highlights execution risks tied to future task orders amid no commercial equity exposure.

1 total filings
· daily

General Federal Contracts — March 18, 2026

NASA's $109.2M delivery order to Caltech (JPL operator) affirms long-term federal commitment to space science R&D through 2028, with $90.3M already outlayed and $16.2M in unexercised options. As a non-profit FFRDC award, it carries neutral direct equity implications but signals execution risks tied to future task orders. Investors should monitor for spillover to commercial space partners amid stable NASA funding.

1 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — March 18, 2026

Across 50 filings in the USA S&P 500 Consumer Staples stream (with broader exposure via related filings), proxy statements dominate, signaling peak AGM season in Q2 2026 with 10+ meetings (e.g., Wells Fargo April 28, Primo Brands April 28, Piedmont May 12), emphasizing governance and compensation votes amid stable sector backdrop. Financial reporters show robust revenue growth averaging ~30% YoY (e.g., Accelerant +51.5%, Five Below +22.9% FY25, Envela +33.6%), driven by expansion and M&A, but mixed profitability with margin compressions (Envela -220 bps, PGIM yield -122 bps) and swing losses (Accelerant -$1.35B). Staples highlights include General Mills earnings release and McCormick controller transition (neutral), while Primo Brands post-merger proxy underscores beverage stability. M&A/capital activity surges (FingerMotion acquisition, Energy Fuels ASM deal, Accelerant $200M buyback), but dilution risks in microcaps (Artelo bridge notes, ECD notes). Portfolio trends: 7/12 metric-rich filings report YoY revenue acceleration vs flat/decline in laggards like Actelis (-53%), positioning outperformers for catalysts. Implications: favor growth names with guidance (Five Below FY26 $5.2-5.3B sales), monitor proxies for comp changes, avoid dilution traps.

28 high priority 22 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — March 18, 2026

Across 50 filings from diverse sectors (heavy in financials despite Industrials focus), overarching themes include robust M&A activity in banking (e.g., Heritage Commerce merger supplements, Independent Bank $70M deal 6% accretive), mixed financial performance with revenue growth in outliers like Tecogen (+19.7% YoY to $27M) and Hills Bancorp (assets +4.5%, net income +27.1%), but margin pressures (Tecogen gross margins -730bps to 36.3%, Home Depot operating income -2.9%). Period-over-period trends show YoY revenue growth averaging ~10% in reporting firms (e.g., Spire FY25 $71.6M, Tecogen +20%), NIM expansions in banks (+67bps at Hills), but widening losses (Tecogen net loss +73% to $8.25M Q4) and flat incomes (Golden Growers +0.3%). Capital allocation leans toward dividends (Great Southern $0.43/share), debt extensions (Hilton RCf maturity extended), and equity issuances for M&A/growth. Critical developments: Advancing acquisitions (Great Lakes HSR cleared), positive guidance (Spire FY26 rev $75-85M, +41-61% ex-maritime), and leadership stability awards (Eagle Bancorp $1.175M continuity pay). Portfolio-level: Industrials subset shows resilient growth amid macro volatility, with M&A catalysts driving near-term upside but litigation risks in deals.

28 high priority 22 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — March 18, 2026

Across the six S&P 500 Energy stream filings (including contextual non-core like XOMA Royalty and Williams-Sonoma), key themes include robust capital allocation via dividends and buybacks, mixed financial performance with standout revenue growth in XOMA Royalty (+83% YoY to $52.1M) and Williams Companies (Adjusted EBITDA +9% YoY to $7.75B), contrasted by revenue declines at Williams-Sonoma (-4.2% YoY Q4 FY25). Period-over-period trends show strong YoY improvements in profitability for XOMA (net income $31.7M vs $13.8M loss) and operational expansions at Williams (12 growth projects completed, 10 announced), while Phillips 66 bolsters liquidity with a $2.25B term loan. Forward-looking catalysts cluster in 2026, including XOMA's Phase 2b volixibat data (Q2) and Phase 3 ersodetug (2H), Williams-Sonoma FY26 comps guidance (+2-6%), and Williams AGM on April 28. Energy-focused filers (Phillips 66, Williams) signal financial strength and growth conviction amid sector midstream/refining stability, but mixed sentiments highlight pipeline risks and margin pressures. Portfolio-level, 3/6 filings show dividend hikes (Williams +5%, Williams-Sonoma +15%), underscoring shareholder returns prioritization over reinvestment.

3 high priority 3 medium 6 total filings
· daily

S&P 500 Financials Sector SEC Filings — March 18, 2026

Across 50 SEC filings in the USA S&P 500 Financials intelligence stream (including banks, REITs, insurers, and adjacent sectors), overarching themes include robust capital returns via dividends (e.g., Great Southern Bancorp $0.43/share Q1 2026) and buybacks (Vistra $5.75B since 2021, NRG $1.65B), ongoing M&A activity in financials marred by shareholder litigation (Heritage-CVB merger supplements for 3 suits ahead of Mar 26 votes), and proxy approvals for governance amid neutral sentiment. Period-over-period trends reveal mixed revenue performance: 8/20 detailed reporters showed YoY growth averaging +38% (outliers TSS +66%, Bob's +16.8%), but 6 reported declines averaging -10% (Macy's -2.4% FY sales, Harte Hanks -13.9%), with margin compressions in 5/12 cases (-40bps avg, e.g., Macy's gross margin). Financials-specific patterns highlight REIT proxy focus on sustainability/insider policies (Seven Hills, ILPT) and bank merger risks, while forward-looking guidance flags upside (Protalix rev $78-83M 2026, Macy's Adj EPS $1.90-2.10). Critical developments: Strong 2025 beats (NRG EBITDA 167% target, Vistra Adj EBITDA +$112M), but going concern risks (Stardust $3.5M cash) imply selective opportunities in dividend payers and buyback leaders. Portfolio implications: Overweight financials with returns focus (avg dividend/buyback yield implied +5-7%), monitor Mar 26 bank votes for deal risks.

26 high priority 24 medium 50 total filings